⁍ Novavax expects to begin producing vaccine at large scale in the beginning of 2021.
⁍ The U.S. government agreed to pay Novavax $1.6 billion to help cover costs related to testing and manufacturing the vaccine.
– The US government plans to spend $1.6 billion to develop a vaccine against a deadly virus that has killed hundreds of people around the world. The goal is to get 100 million doses of Novavax’s vaccine, NVX-CoV2373, into the hands of hospitals and doctors by January 2021, reports the Wall Street Journal. The move is part of the White House’s “Operation Warp Speed” program to make vaccines available to as many people as possible, per Reuters. NVX-CoV2373 is being developed in collaboration with the University of Maryland Medical Center. It’s designed to fight the deadly strain of coronavirus, known as COVID-19, which has killed hundreds of people in Africa, the Middle East, and Asia. Last week, Novavax said its vaccine produced high levels of antibodies in healthy volunteers after two doses, reports Reuters. The company expects to start a large, late-stage clinical trial as soon as later this month.
Source: https://www.reuters.com/article/us-health-cornavirus-novavax-vaccine/novavax-expects-it-can-meet-us-covid-19-vaccine-demand-in-2021-executives-say-idUSKCN2562MP